Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: John Curtis who wrote (777)	5/17/1999 10:24:00 AM
From: StockMiser	Read Replies (1) \| Respond to of 2344

Some indirect news from RIBI: biz.yahoo.com Ribi's Detox-B Immunostimulant Included in Positive Results of Biomira's Theratope(R) Vaccine Presented at ASCO HAMILTON, Mont., May 17 /PRNewswire/ -- Ribi ImmunoChem Research, Inc. (Nasdaq: RIBI - news) announced today that its Detox-B adjuvant was included in two positive studies of Biomira Inc.'s Theratope® vaccine which were presented on May 15 at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia. Encouraging results were presented in a Bridging Study of Theratope® vaccine in patients with metastatic breast cancer and also in a study of Theratope® vaccine following high-dose chemotherapy and hematopoietic stem cell transplantation in patients with ovarian and breast cancer. Theratope® vaccine (STn-KLH) is a therapeutic vaccine that induces the body's immune system to mount a response against cancerous cells. Ribi's Detox-B adjuvant is a potent immune stimulant, which augments the immune response generated by Theratope® vaccine. ''We are pleased that our Detox-B adjuvant is a part of the regimen with the new formulation of Theratope® vaccine and that Biomira has advanced this product into a pivotal Phase 3 trial,'' said Robert E. Ivy, CEO, President and Chairman of Ribi ImmunoChem. ''Our companies will continue to work together to develop the regimen of Theratope® vaccine and Detox-B, which has the potential to benefit a large number of cancer patients.''* The studies reported at ASCO followed several Phase 2 studies with Theratope® vaccine for metastatic breast cancer in which Biomira's researchers demonstrated that the strength of immune response to the vaccine appeared to be correlated with improved survival. The new studies reported constituted a Bridging Study with an enhanced formulation of its lead product candidate. Charles Vogel, MD, FACP, of the Columbia Cancer Research Network, and colleagues reported that in an interim analysis, the improved formulation of Theratope® vaccine resulted in an enhanced immune response against the target cancer antigen. Biomira entered into a pivotal Phase 3 trial in late 1998 to enroll over 900 patients at approximately 75 sites worldwide after initial results of the Bridging Study suggested that the new formulation was as safe as the earlier version of the drug.